Intellia Therapeutics NTLA Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Design Therapeutics, Inc.DSGN

$2.73M+27.7%

Prime MedicinePRME

$112.48M-6.1%

Iovance Biotherapeutics, Inc.IOVA

$46M-11.8%

Immix Biopharma, Inc.IMMX

$1.04M-2.0%

Sana BiotechnologySANA

$75.33M-17.5%

MeiraGTx Holdings plcMGTX

$12.83M+73.8%

FAQ

What is Intellia Therapeutics's operating lease liabilities (total)?

Intellia Therapeutics (NTLA) reported operating lease liabilities (total) of $73.41M in Q2 2026.

How has Intellia Therapeutics's operating lease liabilities (total) changed year-over-year?

Intellia Therapeutics's operating lease liabilities (total) decreased by 28.4% year-over-year, from $102.59M to $73.41M.

What is the long-term trend for Intellia Therapeutics's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Intellia Therapeutics's operating lease liabilities (total) has grown at a 18.9% compound annual growth rate (CAGR), from $39.31M to $93.33M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.